Outcomes and Database Research

Research Overview and Approach

Work in the lab aims to provide outcomes research in localized and advanced prostate cancer by tracking a large population of prostate cancer patients treated or evaluated at the Duke Prostate Center.

Long-term outcomes study of a very large cohort of men treated for prostate cancer in the Duke Prostate Center provides a better understanding of the causes of this disease. This information will allow us to develop treatment strategies that are individually tailored to a man’s unique characteristics.

Clinical Research Initiatives

Research in the lab involves the following:

  • Prostate cancer epidemiology and determinants of clinical outcomes
  • Clinical database development and bio-specimen banking at Duke University Hospital and the Durham VA Medical Center
  • Analyzing and tracking racial disparities in prostate cancer risk, management, and progression to uncover trends and make recommendations for future care
  • Biomarker discovery, assay development, and optimization for prostate cancer diagnosis and prognostication
  • Statistical modeling and bioinformatics

Contact Information

Director of Database & Outcomes Research

Jonathan C. Routh, MD, MPH
Assistant Professor of Surgery 

Duke University Medical Center
Box 3831, Duke South
Durham, NC  27710

Phone:919-684-6994
E-mail: jonathan.routh@duke.edu

Laboratory Personnel

Leah Gerber
Jim Qi

Representative Publications

Jayachandran J, Schroeck F, Sun L, Gerber L, Moreira DM, Moul JW, Freedland SJ. The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: Validation in the Duke Prostate Center database. BJU International 105(2): 180-184, 2010.

Uhlman MA, Sun L, Stackhouse DA, Caire AA, Polascik TJ, Robertson CN, Madden J, Vollmer R, Albala DM, Moul JW. Tumor volume, tumor percentage involvement, or prostate volume: Which is predictive of prostate-specific antigen recurrence? Urology 75(2): 460-466, 2010.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol 183(3): 946-951, 2010.

Uhlman MA, Sun L, Stackhouse DA, Polascik TJ, Mouraviev V, Robertson CN, Albala DM, Moul JW. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol 183(3): 997-1002, 2010.

Moreira DM, Presti Jr. JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun L, Moul JW, Freedland SJ. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer Prostatic Dis. 13(1): 87-93, 2010.

Caire AA, Sun L, Robertson CN, Polascik TJ, Maloney KE, George DJ, Price MM, Stackhouse DA, Lack BD, Albala DM, Moul JW. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology 75(5): 1122-1127, 2010.

Caire AA, Sun L, Lack BD, Lum K, Tang P, Stackhouse DA, Robertson CN, Mouraviev V, Polascik TJ, Albala DM, Moul JW. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer Prostatic Dis. 13(2): 248-251, 2010.

Bañez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ, Masko EM, Vollmer RT, Freedland SJ. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):722-8. Abstract

Bañez LL, Loftis RM, Freedland SJ, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK. The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):173-7. Abstract

Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G, Castaños-Vélez E. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010 Jul;184(1):149-56. Abstract

Hamilton RJ, Bañez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010 Jul 15;116(14):3389-98. Abstract

Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ. Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database. BJU Int. 2010 Feb;105(3):347-51. Abstract

Moreira DM, Bañez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2010 Jan;105(1):28-33. Abstract

Antonelli JA, Jones LW, Bañez LL, Thomas JA, Anderson K, Taylor LA, Gerber L, Anderson T, Hoyo C, Grant D, Freedland SJ. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol. 2009 Nov;182(5):2226-31. Abstract

Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int. 2009 Aug;104(3):310-4. Abstract

Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug;182(2):491-6; discussion 496-8. Abstract

Bañez LL, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1208-12. Abstract

Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009;12(3):259-63. Abstract

Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ, . Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2009 Nov 15;115(22):5263-71. Abstract

Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ. Preoperative predictors of blood loss at the time of radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2009;12(3):264-8. Abstract

Isariyawongse BK, Sun L, Bañez LL, Robertson C, Polascik TJ, Maloney K, Donatucci C, Albala D, Mouraviev V, Madden JF, Moul JW. Significant Discrepancies Between Diagnostic and Pathologic Gleason Sums in Prostate Cancer: The Predictive Role of Age and Prostate-Specific Antigen. Urology. 2008 Apr 1. Abstract

Jayachandran J, Bañez LL, Levy DE, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ, . Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol. 2008 May;179(5):1791-6; discussion 1796. Abstract

McLerran D, Grizzle WE, Feng Z, Bigbee WL, Bañez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem. 2008 Jan;54(1):44-52. Abstract

Teeter AE, Bañez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ,. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol. 2008 Nov;180(5):1980-4; discussion 1985. Abstract